Voyager Therapeutics, Inc. (VYGR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Voyager Therapeutics, Inc.
Address
75 Sidney Street
Lexington, MA 02139
United States of America (the)
Phone
857 259 5340
Sector
Healthcare
Industry
Biotechnology
Employees
172
First IPO Date
November 11, 2015
Key Executives
| Name | Title | Pay | Year Born |
| Alfred W. Sandrock Jr. | President, Chief Executive Officer & Director | 1.05M | 1958 |
| Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | 0 | 1977 |
| Nathan D. Jorgensen | Chief Financial Officer | 577,748 | 1977 |
| Robin Swartz | Principal Financial Officer, Treasurer, Chief Business Officer & COO | 738,950 | 1971 |
| Mathieu Nonnenmacher | Vice President of Gene Therapy | 0 | N/A |
| Krystof Bankiewicz | Founder | 0 | N/A |
| Mihalis Kariolis | Vice President of Non-Viral Therapeutics | 0 | N/A |
| Gregory Shiferman | Senior VP, General Counsel & Secretary | 0 | 1985 |
| Todd Carter | Chief Scientific Officer | 0 | 1970 |
| Amy Quinlan | Principal Accounting Officer | 0 | 1975 |
| Mark A. Kay | Founder | 0 | 1959 |
Description
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
